Tesamorelin
Tesamorelin (GHRH Analog)
FDA-Approved GHRH Analog for Visceral Fat Reduction
What is Tesamorelin?
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce and release growth hormone. It consists of the 44 amino acids of human GHRH with an added trans-3-hexenoic acid group, which enhances its stability and bioavailability.
Tesamorelin is FDA-approved under the brand name Egrifta for the reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients. It is the only GHRH analog that has received FDA approval specifically for reducing visceral adipose tissue (VAT), the deep abdominal fat that surrounds internal organs and is associated with increased cardiovascular risk.
Beyond its approved use, tesamorelin has attracted interest for its potential benefits in improving body composition, enhancing cognitive function, and supporting overall metabolic health. Studies have shown that tesamorelin can significantly reduce visceral fat while preserving subcutaneous fat and lean muscle mass. It also demonstrates neuroprotective properties and has been studied for its potential to improve cognitive function in older adults and those at risk for Alzheimer's disease.
Tesamorelin works by binding to GHRH receptors in the pituitary gland, triggering a natural pulsatile release of growth hormone. Unlike synthetic HGH, tesamorelin stimulates the body's own production of GH, which helps maintain normal feedback mechanisms.
Research Supply
Source high-purity Tesamorelin for your research
Dosage Guide
Route: Subcutaneous injection, once daily
Dosing Schedule
| Period | Dose |
|---|---|
| FDA-approved dose | 2 mg daily (ongoing as prescribed) |
| Research dose | 1-2 mg daily for 8-12 week cycles |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|---|---|
| 1 mg | 1.0 mL | 100 units |
| 2 mg | 2.0 mL | Use two injections |
Administration Tips
- Inject subcutaneously in the abdomen
- Administer once daily, preferably at bedtime or in the morning on an empty stomach
- Rotate injection sites to prevent irritation
- Do not inject into scar tissue, bruises, or the navel area
- Store reconstituted solution refrigerated and use within 28 days
Risks & Side Effects
Commonly Reported
Serious Risks
Fluid retention
Can worsen pre-existing conditions like carpal tunnel syndrome.
Elevated IGF-1 levels
May increase cancer risk theoretically; monitoring is recommended.
Glucose intolerance
May impair glucose metabolism; monitor blood sugar.
Hypersensitivity reactions
Including rash, urticaria, and rare anaphylaxis.
Pituitary suppression
Potential with long-term use; cycling is recommended.
Contraindications
- Active malignancy (cancer)
- Disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, or pituitary tumor/surgery
- Known hypersensitivity to tesamorelin or mannitol
- Pregnancy (Category X -- known to cause fetal harm)
- Breastfeeding
Frequently Asked Questions
Related Peptides
Experts Covering Tesamorelin
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.